Literature DB >> 23997047

Treatment of pulmonary exacerbations in cystic fibrosis.

Jayesh M Bhatt1.   

Abstract

Pulmonary exacerbations have very important consequences in cystic fibrosis (CF), both in terms of current morbidity as well as implications for long term morbidity and mortality. Even though there is no universally agreed definition of pulmonary exacerbation, prompt and aggressive treatment with a multidisciplinary approach is recommended. Maintenance treatments reduce the risk of exacerbations. Antibiotics should be targeted against the common CF bacteria and these can be given orally, although i.v. antibiotics will be required for ongoing symptoms or severe exacerbations. The evidence base for recommendations regarding the optimal regimens, route and frequency of administration of antibiotics, location, and duration of i.v. antibiotic treatment will be discussed. Management of comorbidities, like poor nutrition and diabetes, is critical in improving outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23997047     DOI: 10.1183/09059180.00006512

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  40 in total

1.  Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.

Authors:  Timothy J Bensman; Joshua Wang; Jordanna Jayne; Lynn Fukushima; Adupa P Rao; David Z D'Argenio; Paul M Beringer
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 2.  Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

Review 3.  Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.

Authors:  Joaquim Gea; Antoni Sancho-Muñoz; Roberto Chalela
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  Antimicrobial Treatment Provides a Competitive Advantage to Mycobacterium abscessus in a Dual-Species Biofilm with Pseudomonas aeruginosa.

Authors:  Graciela Rodríguez-Sevilla; Aurélie Crabbé; Marta García-Coca; John Jairo Aguilera-Correa; Jaime Esteban; Concepción Pérez-Jorge
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

5.  Allergic bronchopulmonary aspergillosis in patient with cystic fibrosis - a case report.

Authors:  Marcela Daniela Ionescu; Mihaela Balgradean; Veronica Marcu
Journal:  Maedica (Buchar)       Date:  2014-12

6.  Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis.

Authors:  Alex H Gifford; Dana B Dorman; Lisa A Moulton; Jennifer E Helm; Mary M Griffin; Todd A MacKenzie
Journal:  Clin Transl Sci       Date:  2015-12-08       Impact factor: 4.689

7.  The association of area deprivation and state child health with respiratory outcomes of pediatric patients with cystic fibrosis in the United States.

Authors:  Gabriela Oates; Sarah Rutland; Lucia Juarez; Annabelle Friedman; Michael S Schechter
Journal:  Pediatr Pulmonol       Date:  2020-12-14

Review 8.  Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy.

Authors:  Victor Emanuel Miranda Soares; Thiago Inácio Teixeira do Carmo; Fernanda Dos Anjos; Jonatha Wruck; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini; Débora Tavares de Resende E Silva
Journal:  Mol Cell Biochem       Date:  2021-09-16       Impact factor: 3.396

9.  SPLUNC1: a novel marker of cystic fibrosis exacerbations.

Authors:  Sara Khanal; Megan Webster; Naiqian Niu; Jana Zielonka; Myra Nunez; Geoffrey Chupp; Martin D Slade; Lauren Cohn; Maor Sauler; Jose L Gomez; Robert Tarran; Lokesh Sharma; Charles S Dela Cruz; Marie Egan; Theresa Laguna; Clemente J Britto
Journal:  Eur Respir J       Date:  2021-11-11       Impact factor: 33.795

10.  Cessation of smoke exposure improves pediatric CF outcomes: Longitudinal analysis of CF Foundation Patient Registry data.

Authors:  Gabriela R Oates; Elizabeth Baker; Joseph M Collaco; Steven M Rowe; Sarah B Rutland; Christopher M Fowler; William T Harris
Journal:  J Cyst Fibros       Date:  2021-07-17       Impact factor: 5.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.